ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Aditya Shreenivas(City Of Hope National Medical Center), Razelle Kurzrock(Medical College of Wisconsin), Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Filip Jankú(The University of Texas MD Anderson Cancer Center), Shumei Kato(Center for Personalized Cancer Treatment), Ben George(Medical College of Wisconsin), Hui‐Zi Chen(Medical College of Wisconsin)
Cited by 89
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Landscape of Microsatellite Instability Across 39 Cancer Types
|JCO Precision Oncology|2017|1.5k
Epstein-Barr Virus and Cancer
|Clinical Cancer Research|2004|795